Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Pneumococcal InfectionsStreptococcus Pneumoniae InfectionsPneumococcal Pneumonia
Interventions
BIOLOGICAL

Pneumococcal Vaccine Formulation 1

0.5 mL, intramuscular (1 middle dose)

BIOLOGICAL

Pneumococcal Vaccine Formulation 2

0.5 mL, intramuscular (2 low doses)

BIOLOGICAL

Pneumococcal Vaccine Formulation 3

0.5 mL, intramuscular (2 middle doses)

BIOLOGICAL

Pneumococcal Vaccine Formulation 4

0.5 mL, intramuscular (2 middle doses)

BIOLOGICAL

Pneumococcal Vaccine Formulation 5

0.5 mL, intramuscular (2 high doses)

BIOLOGICAL

Placebo

0.5 mL, intramuscular

Trial Locations (1)

Unknown

Allschwil

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY

NCT01444339 - Study of Two Investigational Pneumococcal Vaccines in Healthy Adults | Biotech Hunter | Biotech Hunter